Unknown

Dataset Information

0

Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.

ABSTRACT:

Background and aim

Ropeginterferon alfa-2b (P1101) is a novel long-acting mono-PEGylated recombinant proline interferon (IFN) conjugated to a 40 kDa branched polyethylene glycol (PEG) chain at its N-terminus, allowing every-two-week injection. It received European Medicines Agency and Taiwan marketing authorization for the treatment of polycythemia vera in 2019 and 2020, respectively. This phase 2 study aimed to evaluate the pharmacokinetics, safety, and preliminary efficacy of ropeginterferon alfa-2b as compared with PEG-IFN-α2a in patients with chronic hepatitis C virus genotype 1 infection.

Methods

One hundred six treatment naive patients were enrolled in this phase 2 study and randomized to four treatment groups: subcutaneous weekly PEG-IFN-α2a 180 μg (group 1), weekly ropeginterferon alfa-2b 180 μg (group 2), weekly ropeginterferon alfa-2b 270 μg (group 3), or biweekly ropeginterferon alfa-2b 450 μg (group 4) plus ribavirin for 48 weeks.

Results

After multiple weekly administration, serum exposure (AUC0-τ) in ropeginterferon alfa-2b 180 μg was approximately 41% greater and the accumulation ratio of 2-fold greater than PEG-IFN-α2a 180 μg. The incidences of flu-like symptoms were 66.7% (18/27), 53.3% (16/30), 55.0% (11/20), and 48.3% (14/29), anxiety were 14.8% (4/27), 6.7% (2/30), 0%, and 0%, and depression were 25.9% (7/27), 13.3% (4/30), 0%, and 3.4% (1/29), for groups 1-4, respectively. Two grade 2 of 3 depression were noted in PEG-IFN-α2a arm, but none in ropeginterferon arms. The SVR24 rates were 77.8% (21/27), 66.7% (20/30), 80% (16/20), and 69% (20/29), respectively.

Conclusions

Ropeginterferon alfa-2b showed longer effective half-life and superior safety profile than PEG-IFN-α2a. Biweekly injection of ropeginterferon alfa-2b will be studied in larger viral hepatitis patient population.

SUBMITTER: Lin HH 

PROVIDER: S-EPMC8341194 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.
| S-EPMC7587416 | biostudies-literature
Unknown Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.
| S-EPMC7803873 | biostudies-literature
Unknown Population Pharmacokinetics of Ropeginterferon Alfa-2b: A Comparison Between Healthy Caucasian and Chinese Subjects.
| S-EPMC8193675 | biostudies-literature
Unknown Ropeginterferon alfa-2b, a novel IFN?-2b, induces high response rates with low toxicity in patients with polycythemia vera.
| S-EPMC4608390 | biostudies-literature
Unknown Immunomodulatory and direct activities of ropeginterferon alfa-2b on cancer cells in mouse models of leukemia.
| S-EPMC9277408 | biostudies-literature
Unknown Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.
| S-EPMC5411384 | biostudies-literature
Unknown Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
| S-EPMC7027501 | biostudies-literature
Unknown Albinterferon Alfa-2b was not inferior to pegylated interferon-? in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.
| S-EPMC3175757 | biostudies-literature
Unknown Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
| S-EPMC3910820 | biostudies-literature
Unknown Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
| S-EPMC5814891 | biostudies-other